http://opendata.unex.es/recurso/educacion/universidad/personal/6fc2f4837549da19fad2da26d173a704-juan-antonio-carrillo-norte
Relations
- teach:teacherOf
- ou:tienePublicacion
- A rational drug prescription based upon the therapeutic process
- Adinosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer
- Aminopyrine metabolism in man: The acetylation of aminoantipyrine cosegregates with acetylation of caffeine
- Analysis of midazolam and metabolites in plasma by high-performance liquid chromatography: Probe of CYP3A
- Applicability of an Assay for Routine Monitoring of Highly Variable Concentrations of Olanzapine Based on HPLC with Mass Spectrometric Detection
- Are antipsychotic drugs potentially chemopreventive agents for cancer?
- Association of COMT val158met polymorphism with psychopathological symptoms in patients with eating disorders
- BDNF genetic variability modulates psychopathological symptoms in patients with eating disorders
- Bases anatomofisiológicas de la administración de fármacos: formas farmacéuticas y vías de administración
- Biomarcadores genéticos y medicina personalizada: Aplicación en farmacología cardiovascular
- CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: A case control study
- CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine
- Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways
- Clinically significant pharmacokinetic interactions between dietary caffeine and medications
- Comments to 'Interaction between caffeine and clozapine' [4]
- Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H<inf>2</inf>-receptor antagonists
- Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans
- Comparisons of CYP2A6 genotype and enzyme activity between Swedes and Koreans
- Consideraciones sobre la prescripción y utilización de fármacos en personas mayores
- Debrisoquine oxidation in an Italian population: A study in healthy subjects and in schizophrenic patients
- Debrisoquine oxidation phenotype during neuroleptic monotherapy
- Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations
- Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity
- Early detection of drug interactions utilizing a computerized drug prescription handling system - Focus on cerivastatin-gemfibrozil
- Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam.
- Effect of dopamine receptor D4 (DRD4) haplotypes on general psychopathology in patients with eating disorders
- Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients
- Eficacia de un complemento alimenticio con colágeno hidrolizado en la mejora de los índices clínicos de la osteoartritis de rodilla
- El proceso farmacocinético: ¿llega el fármaco al sitio de acción?: distribución de fármacos en el organismo (LADME)
- El proceso farmacocinético: ¿llega el fármaco al sitio de acción?. Absorción de fármacos
- El proceso farmacodinámico: ¿Produce el fármaco el efecto esperado?
- El proceso farmacéutico: ¿llega el fármaco al paciente?: cumplimiento terapéutico y liberación del fármaco
- El proceso terapéutico como base racional de la prescripción farmacológica
- Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions
- Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine
- Excreción de fármacos: el proceso farmacocinético: ¿llega el fármaco al sitio de acción?
- Farmacogenética
- Farmacología: conceptos generales
- Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations
- Funcionalidad familiar y sobrecarga en cuidadores de personas con patología neurológica en la región de Alentejo (Portugal)
- GST polymorphisms interact with dietary factors to modulate lung cancer risk: Study in a high-incidence area
- Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: Characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
- Haplotypes in the 5′-untranslated region of the CYP1A2gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism
- High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in ethiopian population
- Impact of NEGR1 genetic variability on psychological traits of patients with eating disorders
- In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population
- Influence of TFAP2B and KCTD15 genetic variability on personality dimensions in anorexia and bulimia nervosa
- Influence of dopamine polymorphisms on the risk for anorexia nervosa and associated psychopathological features
- Influence of drug use on the ability of older people to develop basic activities
- Interacciones farmacológicas y relevancia clínica: Todo comenzó con el queso
- Interaction of genetic and environmental factors in pharmacogenetics
- Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)
- Medicamentos genéricos: contener el gasto farmacéutico pero con garantias de calidad
- Medicamentos genéricos sí, pero no a cualquier precio
- Medicamentos genéricos: ¿es suficiente la demostración de bioequivalencia para asegurar calidad, eficacia y seguridad?
- Melanocortin-4 receptor gene variants are not associated with binge-eating behavior in nonobese patients with eating disorders
- Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors
- Metabolismo de fármacos en el organismo: el proceso farmacocinético: ¿llega el fármaco al sitio de acción?
- Modulation of midazolam 1-hydroxylation activity in vitro by neurotransmitters and precursors
- N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians
- N-acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in serbs: Unprecedented high prevalence of rapid acetylators in a white population
- Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy
- Pharmacogenetics of cytochrome P450 (CYP) 1A2 and variability in psychotropic drug response
- Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients
- Pharmacology general concepts
- Polymorphic oxidation of debrisoquine in lung cancer patients
- Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients
- Polymorphisms in serotonergic genes and psychopathological traits in eating disorders
- Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: Modulation by endogenous compounds
- Promoting appropriate drug use through the application of the Spanish drug-related problem classification system in the primary care setting
- Protocolo de actuación en pacientes con heridas neoplásicas: cuidados de confort y de los aspectos psicológicos, emocionales y de autoestima
- Relevancia de los polimorfismos genéticos en la respuesta farmacológica
- Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine
- The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 C3435T polymorphisms and gender on the urinary excretion of the metabolites of the H<inf>1</inf>-receptor antihistamine ebastine: A pilot study
- The pharmaceutical process: is the drug getting into the patient? Compliance of drug therapy and drug delivery
- The pharmacokinetic process: is the drug getting to its site of action? Drug absorption
- Thrombocytopenia and fatality associated with olanzapine [2]
- Using a computerized drug prescription screening system to trace drug interactions in an outpatient setting
- Utilización de fármacos en los pacientes mayores
- Volumen de distribución de fármacos: un dato aparente en farmacología
- Xanthine oxidase activity is influenced by environmental factors in Ethiopians
- [Anatomophysiological bases of drug administration. Dosage forms and routes of administration].
- [Drug interactions and clinical relevance: it all began with cheese].
- [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality].
- [Generic medications, yes, but not at any price].
- [Genetic biomarkers and personalized medicine: application in cardiovascular pharmacology].
- [Pharmacokinetic process: does the site of drug action? Excretion of drugs].
- [The pharmacodynamic process: is the drug producing the required effect?].
- [The pharmacokinetic process: is the drug getting to its site of action?: Drug metabolism].
- [The pharmacokinetic process: is the drug getting to its site of action?: Drug distribution (ADME)]. | El proceso farmacocinético: Ilega el farmaco al sitio de accion? Distribucion de fármacos en el organismo (LADME).
- [Volume of distribution of drugs: an apparent data in pharmacology].
- ou:perteneceAGrupoInvestigacion
- ou:imparteDocenciaEnArea
- ou:adscritoACentro
- ou:adscritoADepartamento
